Gallamini A, Di Raimondo F, La Nasa G, et al. Standard therapies versus novel therapies in Hodgkin lymphoma. Immunol Lett. 2013;155(1-2):56-59. doi: 10.1016/j.imlet.2013.09.011. Epub 2013 Oct 16. |
Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. .Clin Cancer Res. 2013;19(24):6812-6819. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18. |
Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070-3076. doi: 10.1093/annonc/mdt413. Epub 2013 Oct 22. |
Venkataraman G, Kamran Mirza M, Eichenauer DA, et al. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014 Feb 4. doi: 10.1111/bjh.12759. [Epub ahead of print] |
ESH International Conference on Lymphomas
Marseille, France, 28–30 October 2012
Expert Rev. Hematol.6(1), 35–37 (2013)
Download
|
Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat. Rev. Clin. Oncol.9(8),450–459(2012). |
Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med.362(10),875–885(2010). |
Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol.29(32),4234–4242(2011). |
Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood119(26),6379–6381(2012). |
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol.30(18),2183–2189(2012). |